Diffuse large B-cell lymphoma (DLBCL) stage 4 is an advanced cancer. Despite its aggressive nature, DLBCL usually responds well to treatment, and new therapies are being developed to help improve ...

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...

Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...

Please provide your email address to receive an email when new articles are posted on . Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed ...

How Does Zynlonta Work for B-Cell Lymphoma? Zynlonta is an antibody drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs work as smart bombs to find cancer cells in the body that ...

B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...